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Abstract
Backgrounds: A potential strategy for the diagnosis of lung cancer is to exploit the distinct metabolic signature of
this disease by way of biomarkers found in different sample types. In this study, we investigated whether specific
volatile organic compounds (VOCs) could be detected in the culture medium of the lung cancer cell line A549 in
addition to the urine of mice implanted with A549 cells.
Results: Several VOCs were found at significantly increased or decreased concentrations in the headspace of the
A549 cell culture medium as compared with the culture medium of two normal lung cell lines. We also analyzed
the urine of mice implanted with A549 cells and several VOCs were also found to be significantly increased or
decreased relative to urine obtained from control mice. It was also revealed that seven VOCs were found at
increased concentrations in both sample types. These compounds were found to be dimethyl succinate, 2-
pentanone, phenol, 2-methylpyrazine, 2-hexanone, 2-butanone and acetophenone.
Conclusions: Both sample types produce distinct biomarker profiles, and VOCs have potential to distinguish
between true- and false-positive screens for lung cancer.
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Background
A 2008 report issued by the WHO [1], estimates that
about 18% of all of cancer deaths can be attributed to
lung cancer. Annually, lung cancer accounts for about
1.3 million deaths worldwide. For this reason, the devel-
opment of a novel diagnostic test, which can facilitate
the early detection of lung cancer, has the ability to
vastly reduce lung cancer mortality rates. Although
many studies report the utility of diagnostic imaging
such as X-ray and CT scan, these modalities are both
expensive and susceptible to false positive and false
negative results.
The ability to combine imaging techniques with other
methodologies such as biomarkers is a strategy with the
potential to enhance the detection of lung cancer [2-4].
Although various biomarkers from blood, saliva and
urine have been detected, including proteins, tumor
antigens, anti-tumor antibodies, cell type-specific pep-
tides, metabolic products and epigenetic phenomena
such as hyper-methylated DNA, RNA, and the expres-
sion of specific genes [5], to date none of these biomar-
kers has had the adequate sensitivity, specificity and
reproducibility to be considered for use clinically.
The analysis of exhaled breath for endogenous volatile
organic compounds (VOCs) is one possible example of
a non-invasive diagnostic assay that can be applied to
cancer patients [6-9]. Current examples include the
13C-
urea breath test for the detection of Helicobacter pylori
[10,11], and the hydrogen-based breath test for carbohy-
drate malabsorption [12]. Another example is acetone,
which is found at increased concentrations in the
exhaled breath of patients with uncontrolled diabetes
mellitus [13].
Sulfur-containing compounds such as ethylmercap-
tane, dimethylsulfide and dimethyldisulfide contribute to
the characteristic odor of patients with liver cirrhosis
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typical of patients suffering from uremia [15]. Ethane
and pentane increase in concentration alongside the
concentration of lipid peroxidation [16,17].
Several studies have shown that potential biomarkers
for lung cancer are low molecular weight VOCs, which
can be detected in the breath of lung cancer patients
[18-24]. For example, a recent study using solid phase
micro-extraction followed by gas chromatography
showed that 1-butanol and 3-hydroxy-2-butanone is
found at significantly higher concentrations in the
breath of lung cancer patients compared with the con-
trol group [25]. Dragonieri et al. reported the use of an
“electronic nose” which was able to discriminate
between patients with lung cancer versus those with
chronic obstructive lung disease (COPD) with a rela-
tively high degree of sensitivity and specificity [26].
In addition to exhaled breath, urine is also considered
to be a potential source of VOCs. However, one issue
associated with the analysis of urine is the potential that
VOCs detected in urine samples are derived from exo-
genous sources such as diet or the environment rather
than as a result of the disease. For instance, Willis et al.
reported that dogs could be trained to distinguish
patients with bladder cancer on the basis of urine odor
[27]. However, a follow-up study was unable to repro-
duce these findings in urine samples from patients with
breast and prostate cancer [28]. Matsumura et al. also
reported that sensor mice could be trained to discrimi-
nate between mice with and without tumors demon-
strating that volatile odorants can be used to identify
tumor-bearing mice [29]. Thus, there is mounting evi-
dence that clinically relevant biomarkers for cancer may
be found in urine.
Nevertheless, the cellular and biochemical origin of
endogenous VOCs that have potential as lung cancer
biomarkers are not well understood. A number of arti-
cles have investigated the release of VOCs from human
cancer cells in vitro [25,30-32]. In the human lung carci-
noma cell CALU-1, the release of branched hydrocar-
bons such as 2,3,3-trimethylpentane, 2,3,5-
trimethylhexane, 2,4-dimethylheptane and 4-methyloc-
tane were all found to be increased, whereas levels of
acetaldehyde, 3-methylbutanal, n-butyl acetate, acetoni-
trile, acrolein, methacrolein, 2-methylpropanal, 2-buta-
none, methyl tert-butyl ether and hexanal were all
decreased [31]. In the human lung cancer cell line NCI-
H2087, alcohol 2-ethyl-1-hexanol and alkane 2-methyl-
pentane were found at increased concentrations, com-
pared with acetaldehyde, 2-methylpropanal, 3-
methylbutanal, 2-methylbutanal and n-butyl acetate con-
centration which were found to be decreased [32].
While it has been reported that there may be a correla-
tion between the VOCs detected in cell culture medium
and in exhaled breath [25], no VOCs common to both
urine and cell culture medium have been detected.
In the present study, we compared the VOCs released
from the human lung adenocarcinoma cell line A549 to
two normal lung cell lines, OUS-11 and WI-38 VA1 to
determine whether any cancer specific compounds
could be detected. We also investigated whether urine
specific VOCs could be used to distinguish between
tumor-bearing mice and healthy control mice, and
whether there were any common compounds detected
in both sample types.
Result
Comparative analysis of VOCs in the human lung cancer
and normal lung cell lines
To extract the VOCs, upon reaching confluency the cell
lines were grown for one, two and three weeks. After a
one week incubation period, no dead cells were
observed in any of the cell lines. After two week, some
floating cells were observed and the culture medium
had turned red (all cell lines). After the three week incu-
bation period, many floating cells were observed and in
all cell lines the culture medium was becoming amber.
Thus, the culture conditions of the one and two week
incubation periods ensured that the release of VOCs
into the medium was mostly due to living cells. How-
ever, following three week incubation, cell viability
diminished, indicating that released VOCs were not
derived from the living cells. Typical total ion chromato-
grams (TICs) of VOCs measured in the medium sam-
ples of each cell line after one week incubation are
shown in Figure 1. A sample of media obtained from
the A549 cell lines showed a peak at 12.82 min that was
clearly increased when compared with the control cell
lines. However, the measured TICs were difficult to ana-
lyze because of multiple ion peaks, making it difficult to
find the different EIC peaks in each of the cell lines. To
analyze in more detail, comparative analysis between the
A549 cell line and control cell lines was performed
using XCMS software [33] and statistical analyses.
Under our experimental conditions, an average of 751
ion peaks per sample was detected in the culture med-
ium by XCMS software and statistical analyses. The sig-
nificantly increased or decreased ion peaks (with a p-
value < 0.10 and 1.5-fold higher or lower than average
peak area of the normal control) were selected for iden-
tification. These ion peaks were summarized by decon-
volution analysis of retention time and identified by
spectral library match using the NIST’08 and Wiley
library. However, identification of the VOCs was done
only by means of spectral library matching (higher than
80% match) without confirmation of their retention
times and comparison against a commercially available
standard reagent. In this study, any peaks that could not
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regarded. The summary of determined VOCs by XCMS
analysis are listed in Table 1, which also shows the rate
of change with averaged peak area (using major m/z),
comparing between the A549 and control cells. After a
o n ew e e ki n c u b a t i o np e r i o d ,t h e r ew a sad i f f e r e n c ei n
the concentration of 31 compounds in the A549 cells
compared with the control cells, whereby 18 compounds
w e r ef o u n dt ob es i g n i f i c a n ti n c r e a s e da n d1 3c o m -
pounds were found to be significantly decreased (p <
0.10) (Table 1A). After a two week incubation period
differences in the concentration of 45 compounds
between the A549 and control cells culture medium
were detected whereby 31 compounds were significantly
increased, and 14 compounds were significantly
decreased (p < 0.10) (Table 1B). After the three week
incubation different concentrations were observed in 30
compounds, whereby 28 compounds were significant
increased, and two compounds were significant
decreased (p < 0.10) (Table 1C).
Preparation of the human lung cancer mouse model
To observe the proliferation of the A549 cells implanted
into the mice, tumor size was measured (Figure 2a),
with measurement commencing at day 13 post
implantation. The body weight of the mice was also
recorded (Figure 2b). Although there was a slight
decrease in body weight in the two days following trans-
plantation, this then gradually increased over subsequent
days. There was no significant difference in body weight
between the tumor-bearing and control mice.
Comparative analysis of VOCs from the urine of tumor-
bearing and control mice
The pooled urine samples from the tumor-bearing (n =
24) and control (n = 16) mice were analyzed by head-
space solid-phase microextraction (HS-SPME) and gas
chromatography time-of-flight mass spectrometry (GC-
TOF MS). Two typical TICs of the VOCs obtained from
the urine samples are shown in Figure 3. The chromato-
graphs obtained from urine samples were very similar to
the cultured medium samples, making it difficult to
identify differences between peaks in EICs of the tumor-
bearing and control mice. However, the results obtained
from detailed and comparative analyses of the two
groups did reveal some differences. On average the
chromatogram from each urine sample contained 1493
ion peaks and from this 68 ion peaks were significantly
increased and 65 ion peaks were decreased relative to
the control group (p < 0.10 and characterized by a 1.5-
fold higher or lower than average peak area of the con-
trol). Deconvolution analysis of the retention time of
each peak allowed for the isolation of 76 VOCs that
were significantly increased and six VOCs that were
decreased. The isolated VOCs were picked up by simi-
larity searching using the mass spectral library (NIST’08
and Wiley). Any VOC that could not be determined
because a library match is too low was disregarded.
Table 2 shows the 43 VOCs that were found be highly
similar following a search of the database. However,
these VOCs were identified only by means of spectral
library match (higher than 80% match) without confir-
mation of their retention times and mass spectral by
comparison against a commercially available standard
reagent. Moreover, Table 2 shows the rate of change
with averaged peak area (using major m/z), comparing
between the tumor-bearing and control mice. In the
urine obtained from the tumor-bearing mice, the con-
centration of 43 compounds was different relative to the
control group (p < 0.10), whereby 42 compounds were
significantly increased, and one compound was signifi-
cantly decreased.
Seven VOCs were increased in both the A549 cell
medium and urine from tumor-bearing mice
We also investigated the compounds in more detail that
were increased in both the one and two week culture
medium samples (A549 cells), and urine of the tumor-
bearing mice. Seven compounds were increased in all
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Figure 1 Typical TIC of the VOCs from the culture medium
samples of WI-38 VA13 cells (A), OUS-11 cells (B) and A549
cells (C) after 1-week incubation. The TICs were obtained from
analysis of the samples (200 μL) by HS-SPME (DVB/CAR/PDMS, 50/30
μm, 2 cm) and GC-TOF MS. The extraction temperature was 45°C
and the time was 50 min. Desorption was performed at 240°C for
10 min. The injection was pulsed splitless (closed 3 min) with a 0.75
mm liner. Temperature programming consisted of an initial
temperature 40°C for 5 min, followed by 3°C/min to 240°C with a 5
min hold at this final temperature. The other GC-MS conditions are
described in the Material and Methods.
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Page 3 of 12Table 1 List of the VOCs obtained from the culture medium of A549 cell line that were increased or decreased
A
Increased compound CAS No. Classification fold p-value
1-Dodecanol 112-53-8 alcohols ++ < 0.01
1-Methoxy-2-propanol 107-98-2 ethers +++ 0.02
2,2,4-Trimethyl-1,3-pentanediol diisobutyrate 6846-50-0 esters + 0.09
2,5-Hexanedione 110-13-4 ketones + 0.08
2-Butanone 78-93-3 ketones + 0.06
2-Phenyl-2-propanol 617-94-7 alcohols +++ 0.02
3,3,5-Trimethylcyclohexanone 873-94-9 ketones ++ 0.04
3-Butene-2-one 78-94-4 ketones + 0.03
4-Cyanocyclohexene 100-45-8 nitriles + 0.07
Acetonitrile 75-05-8 nitriles + 0.03
Cyclohexanone 108-94-1 ketones + 0.04
Diethyl ether 60-29-7 ethers ++ < 0.01
Dimethyl succinate 106-65-0 esters ++ 0.06
Ethanol 64-17-5 alcohols +++ 0.01
Isobutyric acid 2-ethyl-3-hydroxyhexyl ester 74367-31-0 esters + < 0.01
Isophorone 78-59-1 ketones ++ 0.02
Orthoformic acid tri-sec-butyl ester 16754-48-6 esters +++ 0.02
tert-Butanol 75-65-0 alcohols + < 0.01
Decreased compound CAS No. Classification fold p-value
1,3-Di-tert-butylbenzene 1014-60-4 hydrocarbons — 0.07
2,4-Dimethyl-1-heptene 19549-87-2 hydrocarbons — 0.04
2,4-Di-tert-butylphenol 96-76-4 phenols - 0.06
2,5-Dimethyl-2,5-hexanediol 110-03-2 alcohols – 0.02
2-Methyl-1-propanol 78-83-1 alcohols – 0.06
4,6-Dimethyl-2-heptanone 19549-80-5 ketones – 0.05
5-Methylnonane 15869-85-9 hydrocarbons - 0.01
Acetophenone 98-86-2 ketones - 0.08
Benzophenone 119-61-9 ketones — 0.04
Benzyl alcohol 100-51-6 alcohols – 0.02
Dichloromethane 75-09-2 halogens - < 0.01
Maltol 118-71-8 pyrans — < 0.01
Styrene 100-42-5 hydrocarbons – 0.05
B
Increased compound CAS No. Classification fold p-value
1-Dodecanol 112-53-8 alcohols +++ < 0.01
2,2,4-Trimethyl-1,3-pentanediol diisobutyrate 6846-50-0 esters + 0.03
2,2,5,5-Tetramethyltetrahydrofuran 15045-43-9 furans + < 0.01
2,2-Dimethyloxetane 6245-99-4 ethers + < 0.01
2,3-Dihydro-4-methylfuran 34314-83-5 furans + < 0.01
2,4,6-Trimethylpyridine 108-75-8 pyridines + 0.01
2,4-Di-tert-butylphenol 96-76-4 phenols + 0.01
2,5-Dimethyl-2,5-hexanediol 110-03-2 diols + 0.03
2-Butanone 78-93-3 ketones ++ < 0.01
2-Hexanone 591-78-6 ketones + 0.04
2-Methoxyfuran 25414-22-6 furans + 0.02
2-Methyl-1-propanol 78-83-1 alcohols + 0.02
2-Octanone 111-13-7 ketones + 0.03
2-Pentanone 107-87-9 ketones + < 0.01
3-Aminopyrazole-4-carboxylic acid 24447-68-5 carboxylic acids + < 0.01
3-Methyl-3-buten-1-ol 763-32-6 alcohols + 0.01
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4-Isopropoxy-2-butanone 32541-58-5 ketones + 0.02
4-Methylbenzyl alcohol 589-18-4 alcohols + < 0.01
Acetonylacetone 110-13-4 ketones ++ < 0.01
Acetophenone 98-86-2 ketones ++ < 0.01
Diethyl ether 60-29-7 ethers ++ < 0.01
Dimethyl succinate 106-65-0 esters +++ < 0.01
DL-1-Phenylethyl alcohol 98-85-1 alcohols + 0.01
Ethanol 64-17-5 alcohols ++ 0.01
Furfural 98-01-1 aldehydes + 0.02
Isobutyric acid 2-ethyl-3-hydroxyhexyl ester 74367-31-0 esters + 0.01
Methyl vinyl ketone 78-94-4 ketones + < 0.01
Orthoformic acid tri-sec-butyl ester 16754-48-6 esters + < 0.01
o-Xylene 95-47-6 hydrocarbons + 0.05
Pyrrole 109-97-7 pyrroles ++ < 0.01
trans-4-Methyl-2-pentene 674-76-0 hydrocarbons + 0.01
Decreased compound CAS No. Classification fold p-value
1,2-Dihydro-2,2,4-trimethylquinoline 147-47-7 quinolines - 0.01
1-Butanol 71-36-3 alcohols - 0.05
2,3-Butanediol 19132-06-0 diols - < 0.01
2-Ethyl-1-hexanol 104-76-7 alcohols - 0.06
2-Methyl-2-hepten-6-one 110-93-0 ketones – < 0.01
3,5-Lutidine 591-22-0 pyridines - < 0.01
Acetonitrile 75-05-8 nitriles – < 0.01
Benzophenone 119-61-9 ketones – < 0.01
Cyclohexanone 108-94-1 ketones - 0.01
Dimethyl disulfide 624-92-0 Sulfurs — 0.09
Isophorone 78-59-1 ketones - 0.02
Maltol 118-71-8 pyrans — < 0.01
Methanethiol 74-93-1 thiols — 0.1
Tributyl phosphate 126-73-8 esters – 0.03
C
Increased compound CAS No. Classification fold p-value
1,4-Diacetylbenzene 1009-61-6 ketones ++ < 0.01
1-Hydroxycyclohexanecarboxylic acid 1123-28-0 carboxylic acids +++ < 0.01
2,2,4-Trimethyl-1,3-pentanediol diisobutyrate 6846-50-0 esters ++ < 0.01
2,4,6-Trimethylpyridine 108-75-8 pyridines ++ 0.02
2,6-Di-tert-butylphenol 128-39-2 phenols + 0.08
2-Butanone 78-93-3 ketones ++ < 0.01
2-Octanone 111-13-7 ketones + < 0.01
3-Methyl-3-buten-1-ol 763-32-6 alcohols + 0.01
3-Octanol 589-98-0 alcohols + 0.01
4-Cyanocyclohexene 100-45-8 nitriles + < 0.01
4-Methylbenzyl alcohol 589-18-4 alcohols ++ < 0.01
Acetophenone 98-86-2 ketones + < 0.01
Benzaldehyde 100-52-7 aldehydes + 0.07
Benzophenone 119-61-9 ketones +++ < 0.01
Benzyl alcohol 100-51-6 alcohols ++ < 0.01
Bisisobutyric acid
2,4,4-trimethylpentane-1,3-diyl ester
74381-40-1 esters ++ 0.02
Carbamic acid, 4-methylphenyl ester 1850-13-1 esters +++ < 0.01
Cyclohexanone 108-94-1 ketones + 0.02
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cinate, phenol, 2-methylpyrazine, 2-hexanone, 2-buta-
none, 2-pentanone and acetophenone could be
identified not only by spectral library match using
NIST’08 and Wiley library but also by matching with
retention time and mass spectral of commercially avail-
able reagents (data not shown).
To determine the concentration of the seven VOCs, a
standard curve was prepared with analysis by HS-SPME.
The standard curves were induced using the peak area
at most abundance m/z value. The calibration measure-
ments were used to determine the limit of detection
(LOD) and subsequent quantification (LOD) of seven
VOCs. Results in Table 3 present the accuracy of the
standard curve. The standard curve of each VOC indi-
cated good linearity in the range of 0.02 μMt o1 0μM
(R
2 = 0.99). The concentration of each VOCs was then
calculated using the respective standard curves. The
quantitative findings, with accompanying statistical ana-
lysis, are summarized in Tables 4 and 5 (cell cultures)
and Table 6 (mice urine). The significance of the results
was calculated by ANOVA.
Summary of the concentration and significant difference
of seven VOCs in culture medium were shown in Tables 4
and 5. After one week incubation, five VOCs in A549 cell
medium were significantly increased (2-butanone, 2-penta-
none, dimethyl succinate, acetophenone, phenol), 2-
methylpyrazine was significantly decreased in comparison
to the VOCs in the DMEM. Four VOCs in A549 cell med-
ium were significantly increased in comparison to the
VOCs in OUS-11 cell medium; 2-butanone (p = 0.001), 2-
pentanone (p = 0.015), 2-methylpyrazine (p =0 . 0 1 2 ) ,
dimethyl succinate (p = 0.023). Five VOCs in A549 cell
medium were significantly increased in comparison to the
VOCs in WI-38 VA13 cell medium; 2-pentanone (p =
0.001), 2-hexanone (p = 0.002), dimethyl succinate (p =
0.016), acetophenone (p = 0.001), phenol (p = 0.011). After
two week incubation, five VOCs in A549 cell medium
were significantly increased (2-butanone, 2-pentanone,
dimethyl succinate, acetophenone, phenol), 2-methylpyra-
zine was significantly decreased in comparison to VOCs in
the DMEM. All seven VOCs in A549 cell medium were
significantly increased in comparison to the VOCs in
OUS-11 cell medium; 2-butanone (p < 0.001), 2-penta-
none (p < 0.001), 2-hexanone (p = 0.008), 2-methylpyra-
zine (p < 0.001), dimethyl succinate (p < 0.001),
acetphenone (p <0 . 0 0 1 )a n dp h e n o l( p =0 . 0 0 1 ) .F i v e
VOCs in A549 cell medium were significantly increased in
comparison to the VOCs in WI-38 VA13 cell medium; 2-
butanone (p = 0.001), 2-pentanone (p = 0.001), 2-hexa-
none (p = 0.039), dimethyl succinate (p < 0.001), acetphe-
none (p <0 . 0 0 1 ) .
Summary of the concentration and significant differ-
ence of all seven VOCs in mice urine was shown in
Table 6. All VOCs were significantly increased in
tumor-bearing mice urine in comparison to the VOCs
in control mice urine; 2-butanone (p = 0.02), 2-penta-
none (p = 0.08), 2-hexanone (p = 0.02), 2-methylpyra-
zine (p = 0.03), dimethyl succinate (p =0 . 0 3 ) ,
acetphenone (p = 0.02) and phenol (p = 0.01).
Discussion
The ability to use the VOCs detected in the urine of
patients with lung cancer as putative tumor markers
T a b l e1L i s to ft h eV O C so b t a i n e df r o mt h ec u l t u r em e d i u mo fA 5 4 9c e l ll i n et h a tw e r ei n c r e a s e do rd e c r e a s e d
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Diethyl ether 60-29-7 ethers ++ < 0.01
Dimethyl succinate 106-65-0 esters +++ 0.01
DL-1-Phenylethyl alcohol 98-85-1 alcohols ++ < 0.01
Ethanol 64-17-5 alcohols ++ 0.09
Furfural 98-01-1 aldehydes + < 0.01
Isobutyric acid 2-ethyl-3-hydroxyhexyl ester 74367-31-0 esters ++ < 0.01
Phenol 108-95-2 phenols + 0.04
p-Tolualdehyde 104-87-0 aldehydes + < 0.01
Pyrrole 109-97-7 pyrroles + < 0.01
omega-Caprolactam 105-60-2 amides ++ < 0.01
Decreased compound CAS No. Classification fold p-value
2,4-Dimethyl-1-heptene 19549-87-2 hydrocarbons – 0.01
Maltol 118-71-8 pyrans — 0.01
A: One week incubation; B: Two week incubation; C: Three week incubation
This table shows the VOCs, which were significantly different (p < 0.10) and more than 1.5 fold different to the averaged peak area (n = 3). The fold change
indicates the difference in the averaged peak area between the A549 human lung cancer cell line and normal lung cells (+++ > 3 fold increase, ++ > 2 fold
increase, + > 1.5 fold increase, — < 3 fold decrease,
– < 2 fold decrease, - < 1.5 fold decrease)
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nosis of lung cancer. In this study, we identified VOCs
derived from three cell lines (A549, OUS-11, WI-38
VA13) and from the urine of mice inoculated with the
A549 human tumor cell line. The compounds were
detected by HS-SPME and analyzed by GC-MS. The
SPME method is simple and highly sensitive, and the in
this study we used a SPME fiber (2 cm divinylbenzene/
carboxen/polydimethylsiloxane: DVB/CAR/PDMS)
which was the most absorbent as shown by the number
of peaks which we were able to detect. Using this fiber,
we analyzed the substances contained in the headspace
of each sample.
Several studies have also reported that VOCs are asso-
ciated with lung cancer [18,20-24]. For most of these
VOCs however, the cancer cells from which they are
derived and their biochemical origins were not deter-
mined, allowing for the possibility that they are
exogenous substances. In this study, we searched for
characteristic compounds derived from lung cancer cells
by comparing the VOCs from lung cancer cells (A549)
and non-tumor cells. Under our experimental condi-
tions, the composition of the detected VOCs was differ-
ent for each cell and further varied according to
incubation period. Moreover, it was found that 18 (one
week incubation), 31 (two week incubation) and 28
compounds (three week incubation) were increased in
the culture medium of A549 cells compared with non-
tumor cells. These compounds mostly consisted of
ketones and alcohols. In the case of the one week incu-
bation group, alcohols (1-methoxy-2-propanol, 2-phe-
nyl-2-propanol and ethanol) were significantly increased,
compared with the control cells. The two week incuba-
tion caused an increase in the concentration of 1-dode-
canol and dimethyl succinate. In the case of the cells
incubated for three week the concentration of 1-hydro-
xycyclohexanecarboxylic acid, benzophenone, carbamic
acid 4-methylphenyl ester and dimethyl succinate were
all increased. However, at the three week incubation
period, many dead cells were observed and the color of
medium was becoming amber, meaning that the VOCs
obtained from this experimental group may not reflect
VOCs derived from living cells. Ten of the VOCs in the
one week and two week incubation period were found
to be common to both groups: dimethyl succinate,
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Figure 2 Tumor measurement and animal body weight in the
lung cancer animal model.( A) Average tumor size in the tumor-
bearing mice. Tumor size was calculated by multiplying the shortest
and longest diameters using digital calipers. (B) The body weight of
the tumor-bearing (solid line) and control mice (dash line). Each
data point indicates an average value with standard deviation. The
days indicate the number of days after transplantation. Body weight
and tumor size of each mouse was recorded every few days.
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Figure 3 Typical TIC of the VOCs from the urine samples
obtained from the tumor-bearing (A) and normal control mice
(B). The TIC was obtained from the analysis of urine samples (200
μL) by HS-SPME (DVB/CAR/PDMS, 50/30 μm, 2 cm) and GC-TOF MS.
The extraction temperature was 45°C and the time was 50 min.
Desorption was performed at 240°C for 10 min. The injection was
pulsed splitless (closed 3 min) with a 0.75 mm liner. Temperature
programming was set at an initial temperature of 40°C for 5 min,
then programmed at 3°C/min to 240°C with a 5 min hold at this
final temperature. All other GC-MS conditions are described in the
Material and Methods.
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Page 7 of 12diethyl ether, ethanol, 2,2,4-trimethyl-1,3-pentanediol
diisobutyrate, isobutyric acid 2-ethyl-3-hydroxyhexyl
ester, 2-butanone, 1-dodecanol, 3-butene-2-one, ortho-
formic acid tri-sec-butyl ester and 2,5-hexanedione.
These include the plasticizer-like compounds (e.g. 2,2,4-
Trimethyl-1,3-pentanediol diisobutyrate). Thus, it is
necessary to consider the possibility that exogenous
compounds were also detected. Filipiak et al. also
reported that the concentration of ethanol was signifi-
cantly increased in A549 cells, although this finding was
made under different experiment conditions [34]. How-
ever, some of the VOCs identified in cultured medium
of the A549 cells differ from the compounds reported
by Filipiak. The culture conditions and extraction meth-
ods (thermal desorption vs solid-phase microextraction)
may be responsible for this difference. It has also been
reported that 2-butanone was increased in the cultured
medium of NCI-H2087 and CALU-1 lung cancer cell
lines, although not at remarkably high levels [31,32].
Additionally, Sponring et al. has also suggested that 2-
butanone may be increased in the breath of lung cancer
patients [32]. The reason for the differences in the
release or consumption of VOCs among the investigated
cell lines is currently unknown, but may result from
phenotypic or genotypic differences. The differences
may also reflect the characteristics of the specific cell
lines tested.
We created a mouse model of human lung cancer, and
analyzed the VOCs obtained from the urine of these
mice. When the urinary VOCs of the tumor-bearing
mice were compared with of the control group differ-
ences in 43 compounds was observed (42 were increased
and one was decreased). Matsumura et al. created a
mouse lung cancer model, and identified the characteris-
tics of some VOCs from the urine of these animals,
including that 2-heptanone, 5-heptene-2-one were able
to distinguish between the lung cancer group and the
control group [29]. According to our results, 2-hepta-
none and 5-heptene-2-one were identified as being sig-
nificantly increased in the urine of the lung cancer group.
Table 2 List of the VOCs obtained from the tumor-
bearing mice that were increased or decreased relative
to the control group.
Increased compound CAS No. Classification fold p-
value
1,3-Di-tert-butylbenzene 1014-60-4 ethers + 0.08
2-(sec-butyl)-4,5-
dihydrothiazole
56367-27-
2
sulfurs ++ 0.01
2,4-Dimethylheptane 2213-23-2 hydrocarbons + < 0.01
2,5-Dimethylpyrazine 123-32-0 pyrazines + 0.07
2,5-Heptanedione 1703-51-1 ketones + 0.03
2-Acetyl-5-methylfuran 1193-79-9 furans + 0.02
2-Aminobenzamide 88-68-6 aldehydes + 0.05
2-Butanone 78-93-3 ketones + 0.02
2-Ethyl-5-methylfuran 1703-52-2 furans + 0.06
2-Heptanone 110-43-0 ketones + 0.04
2-Hexanone 591-78-6 ketones + 0.03
2-Methoxy-5-
methylthiophene
31053-55-
1
sulfurs + 0.02
2-Methylfuran 534-22-5 furans ++ 0.01
2-Methylpyrazine 109-08-0 pyrazines ++ 0.07
2-Pentanone 107-87-9 ketones + 0.09
2-Methyl-6-vinylpyrazine 13925-09-
2
pyrazines ++ 0.02
3-Hexanone 589-38-8 ketones + 0.1
3-Methyl-1-hexen-3-ol 55145-28-
3
alcohols ++ 0.01
4-Heptanone 123-19-3 ketones + 0.03
4-Ketoisophorone 1125-21-9 ketones + 0.05
4-Methoxyphenol 150-76-5 phenols + 0.02
4-Methyloctane 2216-34-4 hydrocarbons + 0.02
5-Hepten-2-one 6714-00-7 ketones + 0.04
6-methyl-3-heptanone 624-42-0 ketones + 0.03
Acetone 67-64-1 ketones + 0.03
Acetophenone 98-86-2 ketones + 0.03
Benzaldehyde 100-52-7 aldehydes + 0.03
Dimethyl succinate 106-65-0 esters + 0.05
Dimethyl trisulfide 3658-80-8 sulfurs + 0.04
Dimethylamine 124-40-3 amines ++
+
0.1
exo-Brevicomin 20290-99-
7
ethers + 0.03
gamma-Crotonolactone 497-23-4 esters + 0.05
gamma-Hexanolactone 695-06-7 esters + 0.02
Maltol 118-71-8 pyrans + 0.02
N,N-Dimethylacetamide 127-19-5 amines + 0.08
N-Benzylidenemethylamine 622-29-7 amines ++
+
0.06
Phenol 108-95-2 phenols + 0.01
Phenylacetone 103-79-7 ketones + 0.07
p-Toluidine 106-49-0 amines + 0.03
Pyrazinamide 98-96-4 amides + 0.01
Quinazoline 253-82-7 Quinazolines ++
+
0.07
Trimethylamine 75-50-3 amines + 0.02
Table 2 List of the VOCs obtained from the tumor-bear-
ing mice that were increased or decreased relative to the
control group. (Continued)
Decreased compound CAS No. Classification fold p-value
4-Methyl-6-hepten-3-one 26118-97-
8
ketones – < 0.01
This table shows the VOCs, which were significantly different (p < 0.10) and
more than 1.5 fold different to the averaged peak area (n = 3). The fold
change indicates the difference in the averaged peak area between the
tumor-bearing mice and normal control mice (+++ > 3 fold increase, ++ > 2
fold increase, + > 1.5 fold increase, — < 3 fold decrease, – < 2 fold decrease,
- < 1.5 fold decrease).
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2-pentanone, phenol, 2-methylpyrazine, 2-hexanone, 2-
butanone, acetophenone) were increased in both the
urine of the tumor-bearing mice and the culture med-
ium of the A549 cells. These compounds were identi-
fied not only by spectral library matching with
NIST’08 and the Wiley library but also by matching
the retention times and mass spectrum of commer-
cially available reagents. However, with respect to
which culture period is the optimal condition with
which to compare with the in vivo model, it is difficult
to nominate a culture period that closely mimics the
characteristics of the cancer cells in the mice 26-30
days after transplantation.T h ec o n d i t i o n so ft h et w o
week culture period are expected to be similar to the
tumor-bearing mice, based on the idea that it takes a
few days from seeding the cells until they are conflu-
ent. 2-Butanone, 2-pentanone, dimethyl succinate, and
acetophenone in A549 culture medium were signifi-
cantly increased in comparison to other samples
including DMEM only. So these five VOCs considered
suitable candidates for cancer biomarkers. Since 2-
methylpyrazine and 2-hexanone are not likely to be
released from A549 cancer cell, we currently made a
conclusion to discard these compounds from candi-
dates for biomarker. O’Nell et al. reported that 2-buta-
none and acetophenone can be detected in the exhaled
breath of lung cancer patients [35]. It has also been
reported that benzaldehyde, 2-butanone and acetophe-
none are three of the compounds identified as poten-
tial breath markers for lung cancer, in a test which has
80% sensitivity and 100% specificity for the diagnosis
of lung cancer [36].
B a s e do nt h er e s u l t so b t a i n e df r o mt h i ss t u d y ,i t
could be also suggested that some of the VOCs unique
to lung cancer may also be detected in urine. Our
results provide preliminarye v i d e n c et h a tu r i n a r yb i o -
markers may also represent a feasible method for the
early detection and non-invasive diagnosis of lung
cancer.
Table 3 Summary of common VOCs from cells and mice
Compound CAS classification Retention time of standard
(min)
Quantified ion
(m/z)
Range of calibration
(μM)
R
2 LOD
(μM)
LOQ
(μM)
2-Butanone 78-93-3 ketones 10.5 72 0.1-10 0.992 0.058 0.176
2-Pentanone 107-87-
9
ketones 14.7 86 0.02-10 0.999 0.006 0.017
2-Hexanone 591-78-
6
ketones 19.8 100 0.1-10 1.000 0.014 0.042
2-
Methylpyrazine
109-08-
0
pyrazines 27.0 94 0.05-10 1.000 0.004 0.013
Dimethyl
Succinate
106-65-
0
esters 36.3 115 0.1-10 1.000 0.014 0.043
Acetophenone 98-86-2 ketones 38.1 105 0.02-10 1.000 0.033 0.101
Phenol 108-95-
2
phenols 45.6 94 0.1-10 1.000 0.011 0.033
Calibration were performed, giving the calibration curve, the limit of detection (LOD) and limit of quantitation (LOQ)
Table 4 Summary of VOCs detected in headspace of culture medium after one week incubation
Compound OUS-11-1w WI-38 VA13-
1w
DMEM A549-1w A549 vs. OUS-11 A549 vs. WI-38
VA13
A549 vs. DMEM
Average
(μM)
SD Average
(μM)
SD Average
(μM)
SD Average
(μM)
SD p-value
(ANOVA)
Ratio
(A549/
OUS-
11)
p-value
(ANOVA)
Ratio
(A549/
WI-38
VA13)
p-value
(ANOVA)
Ratio
(A549/
DMEM)
2-Butanone 4.656 0.165 13.826 0.945 0.554 0.104 13.418 1.452 0.001 2.9 0.756 1.0 < 0.001 24.2
2-Pentanone 0.220 0.030 0.384 0.006 0.048 0.003 0.312 0.010 0.015 1.4 0.001 0.8 < 0.001 6.4
2-Hexanone 0.034 0.001 0.043 0.002 0.035 0.002 0.033 0.001 0.256 1.0 0.002 0.8 0.284 0.9
2-
Methylpyrazine
< LOD 0.004 0.000 0.016 0.003 0.004 0.001 0.012 - 0.337 0.9 0.004 0.2
Dimethyl
Succinate
0.046 0.001 0.045 0.001 < LOD 0.055 0.004 0.023 1.2 0.016 1.2 < 0.001 -
Acetophenone 0.403 0.026 0.647 0.019 < LOD 0.465 0.020 0.055 1.2 0.001 0.7 < 0.001 -
Phenol 0.099 0.002 0.160 0.003 0.041 0.001 0.095 0.020 0.835 1.0 0.011 0.6 0.019 2.3
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Cell lines and culturing
Three different human cell lines were used in the
experiments: A549 (JCRB No. JCRB0076), OUS-11
(JCRB No. JCRB1034), WI-38 VA13 (JCRB No.
JCRB9057). The A549 cells were originally isolated from
a lung carcinoma of a 58-y-old man and are character-
ized by the presence of a mutated K-ras but a wild-type
B-raf gene. The OUS-11 and WI-38 VA13 cells were
used as normal control cells for the purposes of com-
parison and were derived from normal tissue of lung
cancer patient and from a SV40 virus transformed lung
fibroblast cell line, respectively. The cell lines were
obtained from the Health Science Research Resource
Bank (Osaka, Japan). All cells have grown in DMEM
high-glucose culture medium (Sigma-Aldrich Japan,
Tokyo) supplemented with 10% fetal bovine serum
(HyClone, Logan, UT), penicillin (30 unit/mL, Meiji
Seika, Tokyo, Japan) and streptomycin (30 μg/mL, Meiji
Seika, Tokyo, Japan). The cells were cultured in two cul-
ture dishes (100 mm × 20 mm) in 10 mL culture
medium and every three days fresh medium was applied.
For all experiments, the cells were cultured under stan-
dard conditions at 37°C in humidified atmosphere con-
taining 5% CO2. For the VOC measurements, the A549,
OUS-11 and WI-38 VA13 cells were incubated for one,
two and three-weeks after all cell lines grew as mono-
layer adherent on the surface of culture dishes. After
this incubation period, the culture medium was col-
lected and stored at -80°C until analysis.
Tumor model mice of A549 cell line and
collection of urine
Five-week-old female C.B-17/lcr-scidJcl mice (CLEA
Japan, Tokyo, Japan) were separated into two groups,
those bearing tumors (n = 24) and those used as con-
trols (n = 16). To establish the human tumor-bearing
model, A549 cancer cells were prepared at a concentra-
tion of 1.0 × 10
8 cells/mL in PBS, and implanted subcu-
taneously into the right ventral flank area by injecting
0.1 mL of the suspension. The control mice were
injected only with 0.1 mL PBS on the same position as
Table 5 Summary of VOCs detected in headspace of culture medium after two week incubation
Compound OUS-11-2w WI-38 VA13-
2w
DMEM A549-2w A549 vs. OUS-11 A549 vs. WI-38
VA13
A549 vs. DMEM
Average
(μM)
SD Average
(μM)
SD Average
(μM)
SD Average
(μM)
SD p-value
(ANOVA)
Ratio
(A549/
OUS-
11)
p-value
(ANOVA)
Ratio
(A549/
WI-38
VA13)
p-value
(ANOVA)
Ratio
(A549/
DMEM)
2-Butanone 4.293 0.184 8.971 0.761 0.767 0.120 14.616 0.570 < 0.001 3.4 0.001 1.6 < 0.001 19.1
2-Pentanone 0.158 0.003 0.203 0.024 0.031 0.002 0.363 0.016 < 0.001 2.3 0.001 1.8 < 0.001 11.6
2-Hexanone 0.030 0.000 0.033 0.000 0.034 0.002 0.037 0.002 0.008 1.2 0.039 1.1 0.150 1.1
2-
Methylpyrazine
< LOD 0.004 0.001 0.015 0.003 0.004 0.000 < 0.001 - 0.750 1.0 0.005 0.3
Dimethyl
Succinate
0.043 0.000 < LOD < LOD 0.052 0.001 < 0.001 1.2 < 0.001 - < 0.001 -
Acetophenone 0.245 0.004 0.311 0.015 < LOD 0.561 0.015 < 0.001 2.3 < 0.001 1.8 < 0.001 -
Phenol 0.077 0.006 0.120 0.005 0.031 0.001 0.129 0.005 0.001 1.7 0.144 1.1 < 0.001 4.1
The VOC concentrations are shown with standard deviations. The p-values were calculated by ANOVA. The ratio is a comparison of average concentrations of
A549 and each samples
Table 6 Summary of VOCs detected in headspace of mice urine
Compound CAS Retention
time (min)
control mice tumor-bearing mice p-value
(ANOVA)
Ratio
(tumor/control)
Average
(μM)
SD Average
(μM)
SD
2-Butanone 78-93-3 10.5 8.808 1.154 13.226 1.297 0.02 1.5
2-Pentanone 107-87-9 14.7 2.180 0.209 2.599 0.142 0.08 1.2
2-Hexanone 591-78-6 19.8 0.085 0.016 0.134 0.010 0.02 1.6
2-Methylpyrazine 109-08-0 27.0 0.201 0.029 0.455 0.109 0.03 2.3
Dimethyl Succinate 106-65-0 36.3 0.237 0.017 0.334 0.038 0.03 1.4
Acetophenone 98-86-2 38.1 2.310 0.499 3.912 0.399 0.02 1.7
Phenol 108-95-2 45.6 1.824 0.207 2.722 0.213 0.01 1.5
The VOC concentrations are shown with standard deviations. The p-values were calculated by ANOVA. The ratio is a comparison of average concentrations of
tumor-bearing mice and control mice
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Page 10 of 12tumor-bearing mice. The day of inoculation was defined
as day 0. The mice were kept in glass-shielded metabolic
cages (Metabolica; Sugiyamagen, Tokyo, Japan) under
sterile conditions and were supplied with radiation steri-
lized feed CE-2 (CLEA Japan, Tokyo Japan) and auto-
claved drinking water, which was provided ad libitum.
After transplantation, urine was collected from the mice
daily, and stored at -80°C until time of analysis. Body
weight and tumor size (the shortest and longest dia-
meters) of each mouse was recorded every few days.
Tumor size was calculated by multiplying the length of
the shortest and longest diameters. The mice were sacri-
ficed 30 days after transplantation. The urine samples
were collected from 26 to 30 days after transplantation.
All animals were treated in accordance with the insti-
tutional guidelines for the care and use of laboratory
animals.
Extraction of VOCs by headspace solid-phase
microextraction
Prior to the analysis of the urine and culture medium,
we sought to determine the optimal suitable SPME
fiber. Four types of SPME fibers (carboxen/polydi-
methylsiloxane: CAR/PDMS, divinylbenzene/carboxen/
polydimethylsiloxane: DVB/CAR/PDMS, polydimethylsi-
loxane/divinylbenzene: PDMS/DVB, Polyacrylate) were
compared with the chromatogram obtained from the
analysis of urine samples. The results of this analysis,
revealed the 2 cm 50/30 μm DVB/CAR/PDMS (Supelco
Corp, Bellefonte, PA, USA) fiber to be the optimal and
this fiber was used for subsequent analyses. The urine
and cell culture medium were centrifuged at 10,000 g
for 5 min and, the supernatant was used for the analysis.
The VOCs from urine and cell culture medium were
extracted by HS-SPME methods using of Combi-pal
auto sampler (CTC Analytics, Switzerland). A 200 mL
sample of the urine or culture medium was applied to a
2 mL crimp top vial and sealed by crimp cap. The vial
was set on Combi-pal and equilibrated for 10 min at 45°
C. The volatile compounds in the headspace were
extracted by SPME fiber for 50 min at 45°C.
Gas chromatography and mass spectrometry
The GC-TOF MS system was composed of a 7890a GC
(Agilent, CA, USA) equipped with an auto sampler
Combi-pal and GCT Premier (Waters, MA, USA) for
time of flight mass spectrometry. The SPME fiber with
absorbed volatile compounds was inserted into the
injection port of the 7890a GC using the auto sampler
and desorbed for 10 min at 240°C. The injection was
pulsed splitless (closed 3 min) with a 0.75 mm liner.
The GC-TOF MS system was equipped with an Inert-
Cap Pure-WAX T.L. column (60 m + 2 m transfer line,
0.25 mm i.d., 0.5 μm thick; GL science, Japan), which
was used for separation and analysis of the desorbed
volatiles. We employed the following chromatographic
protocol for separation before MS analyses: 40°C for 5
min, then programmed at 3°C/min to 240°C with a 5
min hold at this final temperature. Column flow was
constant at rate of 1 ml/min. The injection port was
held at 240°C. Operating parameters for the mass spec-
trometer were as follows: the ion source temperature
was 200°C, ionizing energy at 70 eV, scanning frequency
was 0.2 s/spectrum from m/z 40 to m/z 500. Peak iden-
tification was accomplished through manual interpreta-
tion of spectra and matching against the mass spectral
library (NIST/EPA/NIH mass spectral library (NIST 08);
mass spectral library of drugs, poisons, pesticides, pollu-
tants and their metabolites Wiley, USA) and comparison
with commercially available standard samples, which
were purchased from the Tokyo Chemical Industry
(Tokyo, Japan). Each medium sample was analyzed in
triplicate.
Data processing and quantitative analysis
The chromatographic peak areas were integrated using
the MassLynx 4.1 (Waters, MA, USA). Genesis peak
detection was applied for a list of putatively annotated
ions. Detection and integration of generated ion peak
from electron ionization were also performed using a
XCMS software package version 1.16.3 (http://masspec.
scripps.edu) [33], running under R version 2.10.1
(http://cran.r-project.org/). The significance levels of dif-
ferences between groups were calculated using a stu-
dent’s t-test that come with XCMS software. We also
determined that the “increased extracted ion peaks” had
a p-value of < 0.10, and were 1.5 times higher than the
averaged peak area of the other group. Of those peaks, a
manual inspection of the EIC for each peak was made
to validate the detected peak. Refine the VOC was per-
formed by manual deconvolution based on retention
time and peak shape of each increased extracted ion
peak.
The identified VOCs were quantified using commer-
cially available reagents. For each of the reagents, stock
solutions were made to a concentration of 100 mM
(Sigma-Aldrich, MI, USA) by dissolving them into 1 mL
mixture of water and methanol (1/1 v/v). Calibration
s o l u t i o n so f0 . 0 1 ,0 . 0 2 ,0 . 0 5 ,0 . 1 ,0 . 5 ,1 . 0 ,a n d1 0 . 0μM
were also made up. The standard curves were created
based on the peak areas, which were obtained from HS-
SPME GC-TOF MS analysis of the calibration solution.
The data were analyzed in triplicate. The p-values were
obtained using ANOVA.
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